OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries (News-Medical-Net)

Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex’ license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and …
(read here…)

Related items

• World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center (News-Medical-Net)
• Rexahn, TheraTarget form nano science research collaboration (PharmaBiz)
• Mutated IDH1 gene linked to the progression of gliomas (News-Medical-Net)
• Bayer’s NEXAVAR approved in over 70 countries for the treatment of liver cancer (News-Medical-Net)
• Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation (News-Medical-Net)

Tags: cancer, Inc, Isis, isis pharmaceuticals inc, nano, nanotech, nanotechnology, OncoGenex, payment, Pharmaceuticals, prostate cancer, Technology, TEVA, teva pharmaceutical industries, teva pharmaceutical industries ltd, today

This entry was posted on Monday, December 21st, 2009 at 7:52 pm and is filed under Technology.